Cargando…
Author response to ‘Comment on “Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer” (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)’
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126591/ https://www.ncbi.nlm.nih.gov/pubmed/37113736 http://dx.doi.org/10.1177/17588359231168519 |
| _version_ | 1785030286746058752 |
|---|---|
| author | Hettle, Robert McCrea, Charles |
| author_facet | Hettle, Robert McCrea, Charles |
| author_sort | Hettle, Robert |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10126591 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | SAGE Publications |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101265912023-04-26 Author response to ‘Comment on “Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer” (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)’ Hettle, Robert McCrea, Charles Ther Adv Med Oncol Letter to the Editor SAGE Publications 2023-04-17 /pmc/articles/PMC10126591/ /pubmed/37113736 http://dx.doi.org/10.1177/17588359231168519 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| spellingShingle | Letter to the Editor Hettle, Robert McCrea, Charles Author response to ‘Comment on “Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer” (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)’ |
| title | Author response to ‘Comment on “Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer” (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)’ |
| title_full | Author response to ‘Comment on “Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer” (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)’ |
| title_fullStr | Author response to ‘Comment on “Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer” (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)’ |
| title_full_unstemmed | Author response to ‘Comment on “Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer” (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)’ |
| title_short | Author response to ‘Comment on “Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer” (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)’ |
| title_sort | author response to ‘comment on “population-adjusted indirect treatment comparison of maintenance parp inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer” (ther adv med oncol. 2021 sep 30;13:17588359211049639)’ |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126591/ https://www.ncbi.nlm.nih.gov/pubmed/37113736 http://dx.doi.org/10.1177/17588359231168519 |
| work_keys_str_mv | AT hettlerobert authorresponsetocommentonpopulationadjustedindirecttreatmentcomparisonofmaintenanceparpinhibitorwithorwithoutbevacizumabversusbevacizumabaloneinwomenwithnewlydiagnosedadvancedovariancancertheradvmedoncol2021sep301317588359211049639 AT mccreacharles authorresponsetocommentonpopulationadjustedindirecttreatmentcomparisonofmaintenanceparpinhibitorwithorwithoutbevacizumabversusbevacizumabaloneinwomenwithnewlydiagnosedadvancedovariancancertheradvmedoncol2021sep301317588359211049639 |